BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會

TEACHER

Seth Lieblich

Session 4 – Exit Strategies for Early Stage New Drug Companies

Date:27 July (Wednesday)
Time:  14:00 – 15:30 (GMT+8)

Seth Lieblich

Principal
​8VC

Seth joins 8VC from Amgen where he was in Amgen Business Development’s technology group where he was responsible for search & evaluation and transactions for platform technologies across a number of therapeutic and functional areas. Seth was also responsible for strategic academic partnerships across all therapeutic and geographic areas. Prior to Amgen, Seth was at ZS Associates where he led teams engaging in market research, sales force design, and strategy. Prior to ZS Associates, Seth was co-founder and COO of Protomer Technologies, a Pasadena-based biologics startup. Seth received his Ph.D. in Biochemistry and Molecular Biophysics from the California Institute of Technology and holds a B.S and M.S. in Biochemistry from Brandeis University.

Speech title & Synopsis

.

.